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also quantified from each biopsy. Analysis was by enzyme-linked immuno-
absorbent assay.
The biopsy specimens of the anterior sites showed no difference in
MMPs or TIMPs concentrations in ruptured vs nonruptured aneurysms.
MMP-8 and MMP-9 levels were elevated from the biopsy specimens of
12 ruptured sites compared with the 12 paired anterior wall biopsy sites
(MMP-8, P .001; MMP-9, P .01). Other MMPs and TIMPs showed
no difference. Expression of MMP-8 and MMP-9 was mediated by native
mesenchymal cells. Expression was independent of inflammatory infil-
trate.
Comment: The article suggests a final common pathway in the break-
down of extra cellular matrix in AAA rupture. The corollary, of course, is that
inhibition of MMP-8 or MMP-9 activity could potentially decrease the risk
of aneurysm rupture. Perhaps someday patients with aortic aneurysms
unsuitable for repair will be treated with inhibitors of MMP-9 or MMP-8 in
an attempt to prevent death from aneurysm rupture.
Asymptomatic central venous stenosis in hemodialysis patients
Levit RD, Cohen RM, Kwak A, et al. Radiology 2006;238:1051-6
Conclusion: In patients with a hemodialysis access graft and an asymp-
tomatic central venous stenosis (CVS) of 50%, treatment of the CVS
results in more rapid stenosis progression compared with a nontreatment
approach.
Summary: The authors evaluated the natural history of 50% asymp-
tomatic CVSs in hemodialysis patients. Outcome of serial treatment of CVS
with percutaneous catheter-based techniques (PTA) was also evaluated. All
patients in this study required maintenance procedures for their dialysis
access.
Between 1998 and 2004, 35 patients (19 men, 16 women), with a
mean age of 58.7 years, were found to have asymptomatic CVS of 50%.
CVS was measured by using venograms obtained before and after PTA.
Patients with arm swelling, multiple CVSs, or indwelling catheters, were
excluded. CVS progression was calculated by comparing degrees of stenoses
with serial venographic examinations.
The mean severity of CVSs before intervention was 71% (range, 50% to
100%), with 62% of lesions having associated collateral vessels. Twenty eight
percent of CVSs were not treated. The mean degree of stenosis in the
untreated group was 72% (range, 30% to 100%). Mean progression of
stenosis in the untreated group was –0.8% point per day. No untreated CVS
progressed to symptoms, stent placement, or developed additional CVS.
PTA was used to treat 62 CVS lesions (72%). The mean degree of
stenosis in the treated group was 74% (range, 50% to 100%) before and 40%
(range, 0% to 75%) after treatment. In the treated group, mean progression
of CVS was 0.21% per day after treatment. Six of the 62 treated CVS lesions
were monitored, with symptomatic escalation of the CVS as manifested by
arm swelling, need for stent placement, or development of additional CVS
lesions.
Comment: Treatment of an asymptomatic CVS in a dialysis patient is
not a good thing. One is reminded of the old adage that it is wise to avoid
poking a skunk. A major weakness of this study is that the patients were
undergoing maintenance procedures for their dialysis access. We do not
know if the CVS contributed to the need for the dialysis access maintenance.
It would be interesting to know if there was a higher rate of repeat
procedures for maintenance of dialysis access in patients with treated vs
untreated CVS.
Balloon angioplasty versus implantation of nitinol stents in the super-
ficial femoral artery
Schillinger M, Sabeti S, Loewe C, et al. N Engl J Med 2006;354:1879-88
Conclusion: At 6 months and 12 months, percutaneous angioplasty of
superficial femoral artery stenoses with primary implantation of a self-
expanding nitinol stent is superior to percutaneous angioplasty of superficial
femoral artery stenoses with optional secondary stenting.
Summary: The authors evaluated whether primary implantation of a
self-expanding nitinol stent in the superficial femoral artery yielded superior
anatomic and clinical benefits compared with a policy of percutaneous
transluminal angioplasty with stenting reserved as a secondary option. The
study screened 252 patients for participation, of which 104 were eligible for
randomization. These patients all had chronic limb ischemia and claudica-
tion due to stenosis or occlusion of the superficial femoral artery. Fifty-one
patients underwent primary stent implantation, and 53 patients underwent
angioplasty with secondary stent implantation.
The primary study end point was a rate of restenosis of at least 50% in
the treated segment 6 months after intervention. Restenosis was determined
by computed tomography angiography or digital subtraction angiography
and was measured in the worst angiographic view of the narrowest stent
segment or in the 10-mm segments proximal and distal to the treated
superficial femoral artery segment. Secondary end points included restenosis
as determined by duplex scanning at 3, 6, and 12months. Rutherford’s stage
of peripheral arterial disease maximal walking capacity on the treadmill at 24
hours and at 3, 6, and 12 months were also determined. Amputation and
death at 6 and 12 months were additional secondary end points. The ankle
brachial index was measured at 24 hours, and at 3, 6, and 12 months.
The mean length of the treated arterial segment was 132  71 mm in
the primary stent group vs 127 55mm in the angioplasty/secondary stent
group. In the secondary stent group, 17 patients (32%) had secondary
stenting. At 6 months, the rate of restenosis on angiography was 43% in the
angioplasty group and 24% in the primary stent group (P  .05). At 12
months, rates of restenosis were 63% in the angioplasty group and 37% in the
primary stent group as determined by duplex scanning (P  .01). No
amputations occurred in either group at 6 or 12 months, and one patient
died in the primary stent group at 12 months. Patients in the stent group
walked farther on the treadmill at 6 months (average distance, 363 vs 270
meters; P  .04) and at 12 months (average distance, 387 vs 267 meters; P
 .04). At 12 months the ankle brachial index was higher in the stent group
than in the angioplasty group (P  .03). The rate of stent fracture was 2%.
Comment: This study suggests that the primary use of nitinol stents
may improve what is a relatively poor result of angioplasty and secondary
stenting of the superficial femoral artery. Given that previous studies have
suggested that an exercise program is as effective as or more effective than
angioplasty of the superficial femoral artery, it is a shame that the authors did
not include a control group in their trial. It would also have been nice to
know whether the increased walking distance measured on the treadmill
translated to an increased quality of life for the patients in this study.
Nevertheless, it can be said that given the end points of this trial, the use of
primary stenting with nitinol stents for angioplasty of the superficial femoral
artery, was superior to selective stenting after angioplasty of the superficial
femoral artery.
Homocysteine lowering with folic acid and B vitamins in vascular
disease
The Heart Outcomes Prevention Evaluation (HOPE) Two Investigators. N
Engl J Med 2006;354:1567-77
Conclusion: In patients with vascular disease, supplemental folic acid,
vitamin B6, and B12 do not reduce the risk of major cardiovascular events.
Summary: In observational studies, higher homocysteine levels have
been associated with increased rates of stroke and heart disease. It is known
vitamins B6, B12, and folate can lower homocysteine levels. The purpose of
this study was to determine whether the risk of major cardiovascular events
in patients with vascular disease could be reduced with the use of supple-
mental vitamin therapy.
Patients who were aged 55 years and who had vascular disease or
diabetes were randomly assigned either treatment with placebo or a combi-
nation of 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin
B12. The study enrolled 5552 patients aged55 years and monitored them
for an average of 5 years. The primary end point was a composite of death
from myocardial infarction, stroke, and other cardiovascular causes.
In the treatment group, mean plasma homocysteine levels decreased by
2.4 m/L (0.3 mg/L). In the placebo group, mean plasma homocysteine
increased by 0.8 m/L (0.1 mg/L). Primary outcome end points occurred
in 18.8% of the active therapy group (n  519), and in 19.9% (n  547) of
the placebo group (relative risk [RR], 0.95; 95% confidence interval [CI],
0.84 to 1.07; P  .41). Compared with placebo, vitamin treatment did not
decrease risk of death from cardiovascular causes (RR, 0.96; 95% CI, 0.81 to
1.13) or myocardial infarction (RR, 0.98; 95% CI, 0.85 to 1.14). More
patients in the treated groupwere hospitalized for unstable angina (RR 1.24;
95% CI, 1.04 to 1.49). There were fewer strokes in the active treatment
group than the placebo group (RR, 0.75; 95% CI, 0.59 to 0.97).
Subgroup analysis indicated no heterogenicity of treatment effect in
patients from regions where food had mandatory supplementation of folate
vs regions where food was not supplemented. There was no difference in
treatment affects in patients with the top third of baseline homocysteine
levels or in the patients with the top fifth of homocysteine levels. With
adjustments for age, sex, and treatment assignment, baseline homocysteine
level as a continuous measure was a predictor of cardiovascular events.
Comment: Multiple trials have now demonstrated a lack of efficacy of
supplemental vitamin therapy to decrease cardiovascular events. This is despite
documented lowering of homocysteine levels by the vitamin therapy. This
discordance between epidemiology and results of clinical trials is similar to that
noted for estrogen and antioxidant vitamins. It may be that the epidemiologic
data of homocysteine are confused by confounding variables that cannot be
completely adjusted for inmultivariable analysis. Itmay, however, simply be that
homocysteine is a marker but not a cause of vascular disease.
Massive pulmonary embolism
Kucher N, Rossi E, DeRosa M, et al. Circulation 2006;113:577-82
Conclusion: Mortality of pulmonary embolism in patients with mas-
sive pulmonary embolism (PE) is not reduced by thrombolysis or embolec-
tomy. There does appear to be reducedmortality in patients with massive PE
who have placement of inferior vena cava filters.
JOURNAL OF VASCULAR SURGERY
September 2006684 Abstracts
Summary: The International Cooperative Pulmonary Embolism Reg-
istry (ICOPER) enrolled 2454 consecutive patients with acute PE from
January 1995 throughNovember 1996. Fifty-two institutions in 7 countries
were represented. There were 2392 patients with acute PE and known
systolic blood pressure at presentation. Massive PE was defined as a systolic
arterial pressure90mmHg at presentation.Massive PEwas present in 108
patients (4.5%), and 2284 patients (95.5%) had nonmassive PE. Sixteen
patients with massive PE and 29 patients with nonmassive PE had the
diagnosis of PE at autopsy (P  .01). For patients with massive PE, the
90-day mortality rate was 52.4% (95% confidence interval [CI], 43.3% to
62.1%). For patients with nonmassive PE, the 90-day mortality rate was
14.7% (95% CI, 13.3% to 16.2%). Within 90 days, recurrent PE occurred in
12.6% of patients with massive PE and in 7.6% with nonmassive PE (P 
.001). In patients with massive PE, thrombolysis was performed in 33
patients, catheter embolectomy in one, and surgical embolectomy in three,
for an overall active intervention rate for massive PE of 32%. These treat-
ments were withheld in 68% (n  73).
The 90-day mortality rate was not reduced with thrombolytic therapy:
thrombolysis, 46.6% (95% CI, 31.1 to 64.8%) vs no thrombolysis, 55.1%
(95% CI, 44.3% to 66.7%; hazard ratio 0.79; 95% CI, 0.44 to 1.43). The
incidence of recurrent PE at 90 days was 12% in patients with and without
thrombolytic therapy (P  0.99). Eleven patients received an inferior vena
cava filter. None of these patients had recurrent PE within 90 days, and 10
(90.9%) survived at least 90 days. Inferior vena cava filters were associated
with a decreased 90-day mortality (hazard ratio, 0.12; 95% CI, 0.02 to
0.85).
Comment: It is probably wrong to conclude from these data that
thrombolytic therapy cannot reduce mortality in patients with massive
pulmonary embolism syndrome. ICOPER is a registry. Patients receiving
thrombolytic therapy may have been the worst among the worst. The
apparent significant reduction in mortality associated with inferior vena
cava filters deserves further investigation, but it may also reflect those
patients who are actually well enough to receive a filter. Clearly, im-
proved and more standardized treatment of massive PE syndrome is
needed.
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